---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-002998"
form_type: "8-K"
ticker: "TWST"
cik: "0001581280"
company_name: "Twist Bioscience Corp"
filed_at: "2024-02-02T23:59:59+00:00"
generated_at: "2026-06-06T09:54:53.432840+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Twist Bioscience reports record Q1 revenue of $71.5M (+32% YoY); raises FY2024 guidance to $288M-$293M

## Summary
- Orders increased 19% YoY to $77.5M; NGS revenue grew 61% to $39.4M.
- Net loss of $43.0M ($0.75 per share) vs. $41.8M ($0.74 per share) in prior year.
- Gross margin reached 40.5%, above previous guidance; FY2024 margin guidance raised to 40%-41%.
- Appointed Adam Laponis as CFO; expanded Express Genes service to all prep scales.
- Cash and investments of $311.1M as of Dec 31, 2023.

## SEC filing metadata
- accession: 0001628280-24-002998
- form_type: 8-K
- ticker: TWST
- cik: 0001581280
- company_name: Twist Bioscience Corp
- filed_at: 2024-02-02T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1581280/000162828024002998/0001628280-24-002998-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1581280/000162828024002998/twist-20240202.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-002998
- JSON: https://secwatch.observer/filing/0001628280-24-002998.json
- Plain text: https://secwatch.observer/filing/0001628280-24-002998.txt

## Key facts
- Earnings Releases
  Twist Bioscience Corp reported the first quarter of fiscal 2024 ended December 31, 2023 results: revenue $71.5 million, net income Net loss attributable to common stockholders for the first quarter of fiscal 2024 was $43.0 million, or $0.75 per share, EPS $0.75 per share. Guidance raised.
  - Period: the first quarter of fiscal 2024 ended December 31, 2023
  - Revenue: $71.5 million
  - Net income: Net loss attributable to common stockholders for the first quarter of fiscal 2024 was $43.0 million, or $0.75 per share
  - EPS: $0.75 per share
  - Guidance: raised
  - Result: reported results
  source text: reported financial results and business highlights for the first quarter of fiscal 2024 ended December 31, 2023. "We're starting fiscal 2024 off strong with record revenue of $71.5 million for the first fiscal quarter, coming in above our projection, with a gross margin of 40.5%," said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience. "In SynBio,
  evidence_url: https://www.sec.gov/Archives/edgar/data/1581280/000162828024002998/0001628280-24-002998-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.